Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

@inproceedings{Portell2013ClinicalAP,
  title={Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia},
  author={Craig A Portell and Candice M. Wenzell and Anjali S. Advani},
  booktitle={Clinical pharmacology : advances and applications},
  year={2013}
}
Acute lymphoblastic leukemia (ALL) in adults remains a challenging disease to treat, and novel therapies are needed. Precursor-B ALL comprises 80% of cases, and the CD19 antigen is expressed in nearly all precursor-B ALL patients. Bispecific T-cell-engaging antibodies are novel bioengineered proteins. The bispecific T-cell-engaging antibody blinatumomab engages polyclonal T cells to CD19-expressing B cells. By binding to both CD3 and CD19, blinatumomab physically brings these T cells in close… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

  • MS Topp, N Goekbuget, G Zugmaier
  • ASH Annu Meet Abstr
  • 2012
Highly Influential
10 Excerpts

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours), 4th ed

  • S Swerdlow, E Campo, NL Harris, al et, editors
  • Geneva: World Health Organization;
  • 2008
Highly Influential
13 Excerpts

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

  • MS Topp, N Gökbuget, G Zugmaier
  • Blood
  • 2012
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…